The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review.

ABSTRACT:

Background

Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116.

Methods

A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies.

Results

The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms

SUBMITTER: Xiao N 

PROVIDER: S-EPMC10328638 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature